作者
Ida Viller Tuxen, Kristoffer Staal Rohrberg, Olga Oestrup, Lise Barlebo Ahlborn, Ane Yde Schmidt, Iben Spanggaard, Jane P Hasselby, Eric Santoni-Rugiu, Christina Westmose Yde, Morten Mau-Sørensen, Finn Cilius Nielsen, Ulrik Lassen
发表日期
2019/2/15
期刊
Clinical Cancer Research
卷号
25
期号
4
页码范围
1239-1247
出版商
American Association for Cancer Research
简介
Purpose
We evaluated the clinical benefit of tumor molecular profiling to select treatment in the phase I setting.
Experimental Design
Patients with advanced solid cancers and exhausted treatment options referred to a phase I unit were included in a prospective, single-center, single-arm open-label study (NCT02290522). Tumor biopsies were obtained for comprehensive genomic analysis including whole-exome sequencing and RNA sequencing. When possible, patients were treated with regimen matched to the genomic profile. Primary endpoint was progression-free survival (PFS).
Results
From May 2013 to January 2017, a total of 591 patients were enrolled, with 500 patients undergoing biopsy. Genomic profiles were obtained in 460 patients and a potential actionable target was identified in 352 (70%) of 500 biopsied patients. A total of 101 patients (20 …
学术搜索中的文章
IV Tuxen, KS Rohrberg, O Oestrup, LB Ahlborn… - Clinical Cancer Research, 2019
